August 7, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) maintained its position as the best-selling drug in Japan in July with sales of 11.4 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm Encise. The...read more